Malta - English - Medicines Authority

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - powder and solvent for solution for injection in pre-filled syringe - varicella virus oka strain (live, attenuated) 10pfu/dose - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - varicella vaccine - live; water for injections -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga lifescience sdn. bhd. - live, attenuated varicella zoster virus (oka/sk strain) -

New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - zoster immunoglobulin, human 100 iu/ml (immunoglobulin ex nz) - granules for injection - 200 iu/2ml - active: zoster immunoglobulin, human 100 iu/ml (immunoglobulin ex nz) excipient: glycine - zoster immunoglobulin-vf is indicated for prophylaxis against varicella in patients who meet all four of the criteria listed below: 1. one of the following underlying illnesses or conditions: a. neoplastic disease (leukaemia or lymphoma) b. congenital or acquired immunodeficiency c. immunosuppressive therapy with steroids or antimetabolites. 2. one of the following types of exposure to chickenpox or shingles patients: a. household contact b. playmate contact (> 1 hour play indoors) c. hospital contact (in same 2 to 4 bedroom or adjacent beds in a large ward) d. newborn contact (newborn of mother who had onset of chickenpox < 5 days before delivery or within 48 hours after delivery) e. premature infant (> 28 weeks gestation) whose mother lacks a prior history of chickenpox f. premature infant (< 28 weeks gestation or < 1000g) regardless of maternal history. 3. negative or unknown prior history of chickenpox. 4. if zoster immunoglobulin-vf can be administered within 96 hours after exposure. zoster immunoglobulin-vf, normal immunoglobulin-vf (immunoglobulin for intramuscular use) or plasma are of no value in the treatment of established varicella or zoster infection. high levels of circulating antibody do not prevent dissemination of infection. zoster immunoglobulin-vf is not indicated for prophylactic use in immunodeficient children or adults when there is a history of varicella, unless the patient's immunosuppressed status is that which is associated with bone marrow transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 1995 pfu; rubella virus, quantity: 1000 ccid50; measles virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50 - diluent, not applicable - excipient ingredients: water for injections - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - varicella vaccine - live -

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - pneumococcal vaccine - solution for injection in pre-filled syringe - 25 mcg/0.5 millilitre(s) - pneumococcal vaccines; pneumococcus, purified polysaccharides antigen

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - pneumococcal vaccine - solution for injection - 25mcg/0.5 millilitre(s) - pneumococcal vaccines; pneumococcus, purified polysaccharides antigen

Canada - English - Health Canada

glaxosmithkline inc - varicella-zoster virus vaccine live attenuated (oka-strain); water - powder for solution - 1995pfu; 0.5ml - varicella-zoster virus vaccine live attenuated (oka-strain) 1995pfu; water 0.5ml - vaccines